Literature DB >> 21052020

Renal protective effects of N-acetyl-Ser-Asp-Lys-Pro in deoxycorticosterone acetate-salt hypertensive mice.

Nour-Eddine Rhaleb1, Saraswati Pokharel, Umesh Sharma, Oscar A Carretero.   

Abstract

BACKGROUND: Hypertension-induced renal injury is characterized by inflammation, fibrosis and proteinuria. Previous studies have demonstrated that N-acetyl-Ser-Asp-Lys-Pro (Ac-SDKP) inhibits renal damage following diabetes mellitus and antiglomerular basement membrane nephritis. However, its effects on low-renin hypertensive nephropathy are not known. Thus, we hypothesized that Ac-SDKP has renal protective effects on deoxycorticosterone acetate (DOCA)-salt hypertensive mice, decreasing inflammatory cell infiltration, matrix deposition and albuminuria.
METHOD: We uninephrectomized 16-week-old C57BL/6J mice and treated them with either placebo, DCOA (10 mg/10 g body weight subcutaneous) and 1% sodium chloride with 0.2% potassium chloride in drinking water (DOCA-salt) or DOCA-salt with Ac-SDKP (800 μg/kg per day) for 12 weeks. We measured blood pressure, urine albumin, glomerular matrix, renal collagen content, monocyte/macrophage infiltration and glomerular nephrin expression.
RESULTS: Treatment with DOCA-salt significantly increased blood pressure (P < 0.01), which remained unaltered by Ac-SDKP. Ac-SDKP decreased DOCA-salt-induced renal collagen deposition, glomerular matrix expansion and monocyte/macrophage infiltration. Moreover, DOCA-salt-induced increase in albuminuria was normalized by Ac-SDKP (controls, 10.8 ± 1.7; DOCA-salt, 41 ± 5; DOCA-salt + Ac-SDKP, 13 ± 3 μg/10 g body weight per 24 h; P < 0.001, DOCA-salt vs. DOCA-salt + Ac-SDKP). Loss of nephrin reportedly causes excess urinary protein excretion; therefore, we determined whether Ac-SDKP inhibits proteinuria by restoring nephrin expression in the glomerulus of hypertensive mice. DOCA-salt significantly downregulated glomerular nephrin expression (controls, 37 ± 8; DOCA-salt, 10 ± 1.5% of glomerular area; P < 0.01), which was partially reversed by Ac-SDKP (23 ± 4.0% of glomerular area; P = 0.065, DOCA-salt vs. DOCA-salt + Ac-SDKP).
CONCLUSION: We concluded that Ac-SDKP prevents hypertension-induced inflammatory cell infiltration, collagen deposition, nephrin downregulation and albuminuria, which could lead to renoprotection in hypertensive mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21052020      PMCID: PMC3012752          DOI: 10.1097/HJH.0b013e32834103ee

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  47 in total

1.  Aldosterone/salt induces renal inflammation and fibrosis in hypertensive rats.

Authors:  Eileen R Blasi; Ricardo Rocha; Amy E Rudolph; Eric A G Blomme; Melissa L Polly; Ellen G McMahon
Journal:  Kidney Int       Date:  2003-05       Impact factor: 10.612

2.  N-Acetyl-seryl-aspartyl-lysyl-proline inhibits TGF-beta-mediated plasminogen activator inhibitor-1 expression via inhibition of Smad pathway in human mesangial cells.

Authors:  Keizo Kanasaki; Daisuke Koya; Toshiro Sugimoto; Motohide Isono; Atsunori Kashiwagi; Masakazu Haneda
Journal:  J Am Soc Nephrol       Date:  2003-04       Impact factor: 10.121

3.  Antifibrotic effect of Ac-SDKP and angiotensin-converting enzyme inhibition in hypertension.

Authors:  Saman Rasoul; Oscar A Carretero; Hongmei Peng; Maria A Cavasin; Jialong Zhuo; Alicia Sanchez-Mendoza; David R Brigstock; Nour-Eddine Rhaleb
Journal:  J Hypertens       Date:  2004-03       Impact factor: 4.844

Review 4.  Association between transforming growth factor-beta and hypertension.

Authors:  Paul J Lijnen; Victor V Petrov; Robert H Fagard
Journal:  Am J Hypertens       Date:  2003-07       Impact factor: 2.689

5.  Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension.

Authors:  Ulf Landmesser; Sergey Dikalov; S Russ Price; Louise McCann; Tohru Fukai; Steven M Holland; William E Mitch; David G Harrison
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

6.  Disparate effects of angiotensin II antagonists and calcium channel blockers on albuminuria in experimental diabetes and hypertension: potential role of nephrin.

Authors:  Belinda J Davis; Zemin Cao; Marc de Gasparo; Hiroshi Kawachi; Mark E Cooper; Terri J Allen
Journal:  J Hypertens       Date:  2003-01       Impact factor: 4.844

Review 7.  Renal and vascular oxidative stress and salt-sensitivity of arterial pressure.

Authors:  R D Manning; S Meng; N Tian
Journal:  Acta Physiol Scand       Date:  2003-11

8.  Ac-SDKP reverses inflammation and fibrosis in rats with heart failure after myocardial infarction.

Authors:  Fang Yang; Xiao-Ping Yang; Yun-He Liu; Jiang Xu; Oscar Cingolani; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Hypertension       Date:  2003-12-22       Impact factor: 10.190

9.  Ac-SDKP reverses cardiac fibrosis in rats with renovascular hypertension.

Authors:  Hongmei Peng; Oscar A Carretero; David R Brigstock; Nancy Oja-Tebbe; Nour-Eddine Rhaleb
Journal:  Hypertension       Date:  2003-10-27       Impact factor: 10.190

10.  N-acetyl-Ser-Asp-Lys-Pro inhibits phosphorylation of Smad2 in cardiac fibroblasts.

Authors:  Saraswati Pokharel; Saman Rasoul; Anton J M Roks; Rick E W van Leeuwen; Marja J A van Luyn; Leo E Deelman; Jos F Smits; Oscar Carretero; Wiek H van Gilst; Yigal M Pinto
Journal:  Hypertension       Date:  2002-08       Impact factor: 10.190

View more
  16 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

Review 2.  Cardiovascular diseases in survivors of childhood cancer.

Authors:  Neha Bansal; Javier G Blanco; Umesh C Sharma; Saraswati Pokharel; Shannon Shisler; Steven E Lipshultz
Journal:  Cancer Metastasis Rev       Date:  2020-03       Impact factor: 9.264

Review 3.  Tβ4-Ac-SDKP pathway: Any relevance for the cardiovascular system?

Authors:  Kamal M Kassem; Sonal Vaid; Hongmei Peng; Sarah Sarkar; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-03-09       Impact factor: 2.273

4.  N-acetyl-seryl-aspartyl-lysyl-proline reduces cardiac collagen cross-linking and inflammation in angiotensin II-induced hypertensive rats.

Authors:  Germán E González; Nour-Eddine Rhaleb; Pablo Nakagawa; Tang-Dong Liao; Yunhe Liu; Pablo Leung; Xiangguo Dai; Xiao-Ping Yang; Oscar A Carretero
Journal:  Clin Sci (Lond)       Date:  2014-01-01       Impact factor: 6.124

5.  The anti-inflammatory peptide Ac-SDKP is released from thymosin-β4 by renal meprin-α and prolyl oligopeptidase.

Authors:  Nitin Kumar; Pablo Nakagawa; Branislava Janic; Cesar A Romero; Morel E Worou; Sumit R Monu; Edward L Peterson; Jiajiu Shaw; Frederick Valeriote; Elimelda M Ongeri; Jean-Marie V Niyitegeka; Nour-Eddine Rhaleb; Oscar A Carretero
Journal:  Am J Physiol Renal Physiol       Date:  2016-03-09

6.  N-acetyl-seryl-aspartyl-lysyl-proline treatment protects heart against excessive myocardial injury and heart failure in mice.

Authors:  Hongmei Peng; Jiang Xu; Xiao-Ping Yang; Kamal M Kassem; Imane A Rhaleb; Ed Peterson; Nour-Eddine Rhaleb
Journal:  Can J Physiol Pharmacol       Date:  2019-04-18       Impact factor: 2.273

7.  Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-induced hypertension.

Authors:  Germán E González; Nour-Eddine Rhaleb; Martin A D'Ambrosio; Pablo Nakagawa; Yunhe Liu; Pablo Leung; Xiangguo Dai; Xiao-Ping Yang; Edward L Peterson; Oscar A Carretero
Journal:  J Hypertens       Date:  2015-01       Impact factor: 4.844

8.  Fragment-based design for the development of N-domain-selective angiotensin-1-converting enzyme inhibitors.

Authors:  Ross G Douglas; Rajni K Sharma; Geoffrey Masuyer; Lizelle Lubbe; Ismael Zamora; K Ravi Acharya; Kelly Chibale; Edward D Sturrock
Journal:  Clin Sci (Lond)       Date:  2014-02       Impact factor: 6.124

Review 9.  Rediscovering ACE: novel insights into the many roles of the angiotensin-converting enzyme.

Authors:  Romer A Gonzalez-Villalobos; Xiao Z Shen; Ellen A Bernstein; Tea Janjulia; Brian Taylor; Jorge F Giani; Wendell-Lamar B Blackwell; Kandarp H Shah; Peng D Shi; Sebastien Fuchs; Kenneth E Bernstein
Journal:  J Mol Med (Berl)       Date:  2013-05-18       Impact factor: 5.606

10.  Thymosin β4 and its degradation product, Ac-SDKP, are novel reparative factors in renal fibrosis.

Authors:  Yiqin Zuo; Bongkwon Chun; Sebastian A Potthoff; Naj Kazi; Tyler J Brolin; Diclehan Orhan; Hai-Chun Yang; Li-Jun Ma; Valentina Kon; Timo Myöhänen; Nour-Eddine Rhaleb; Oscar A Carretero; Agnes B Fogo
Journal:  Kidney Int       Date:  2013-06-05       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.